Literature DB >> 16920357

Design of inhibitors against guanase: synthesis and biochemical evaluation of analogues of azepinomycin.

Ravi K Ujjinamatada1, Anila Bhan, Ramachandra S Hosmane.   

Abstract

As part of a program to design rational, mechanism-based inhibitors of guanase, we report here the synthesis and biochemical screening of two analogues of azepinomycin (1 and 2), a naturally occurring inhibitor of guanase, known to mimic the transition-state of the enzyme-catalyzed reaction. Our biochemical results show that compounds 1 and 2 are competitive inhibitors with K(i) of 2.01+/-0.16 x 10(-5) and 5.36+/-0.14 x 10(-5) M, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920357     DOI: 10.1016/j.bmcl.2006.08.033

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  A novel transition state analog inhibitor of guanase based on azepinomycin ring structure: Synthesis and biochemical assessment of enzyme inhibition.

Authors:  Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2010-11-27       Impact factor: 2.823

Review 2.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.

Authors:  José R Fernández; Eric S Sweet; William J Welsh; Bonnie L Firestein
Journal:  Bioorg Med Chem       Date:  2010-07-27       Impact factor: 3.641

4.  Investigations into specificity of azepinomycin for inhibition of guanase: discrimination between the natural heterocyclic inhibitor and its synthetic nucleoside analogues.

Authors:  Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2012-10-02       Impact factor: 2.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.